Australia markets closed

Zealand Pharma A/S (0NZU.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
126.80+8.08 (+6.81%)
At close: 04:30PM GMT
Full screen
Previous close118.72
Open123.20
BidN/A x N/A
AskN/A x N/A
Day's range123.20 - 124.50
52-week range123.20 - 124.50
Volume11,884
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results

    Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on February 27, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year 2023. Present

  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at January 31, 2024

    Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a cale

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: Van Herk Investments

    Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 26 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 25